<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="66148"><DrugName>CLP-1002</DrugName><DrugSynonyms><Name><Value>CLP-1002</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>cross-linked polyelectrolyte polymer (CHF, kidney disease), Sorbent Therapeutics</Value></Name></DrugSynonyms><CompanyOriginator id="1045924">Sorbent Therapeutics Inc</CompanyOriginator><CompaniesSecondary><Company id="1045924">Sorbent Therapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1045924" type="Company"><TargetEntity id="4297348245" type="organizationId">Sorbent Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="1559" type="ciIndication"><TargetEntity id="428.0" type="ICD9"></TargetEntity><TargetEntity id="10007559" type="MEDDRA"></TargetEntity><TargetEntity id="239" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="286" type="ciIndication"><TargetEntity id="10029151" type="MEDDRA"></TargetEntity><TargetEntity id="D007674" type="MeSH"></TargetEntity><TargetEntity id="-966472843" type="omicsDisease"></TargetEntity><TargetEntity id="334" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3251" type="ciIndication"><TargetEntity id="N18.6" type="ICD10"></TargetEntity><TargetEntity id="D007676" type="MeSH"></TargetEntity><TargetEntity id="1890" type="siCondition"></TargetEntity><TargetEntity id="1604" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1559">Congestive heart failure</Indication><Indication id="286">Renal disease</Indication><Indication id="3251">End stage renal disease</Indication></IndicationsSecondary><ActionsSecondary><Action id="2659">Cardioprotectant</Action><Action id="832">Sodium metabolism modulator</Action><Action id="831">Potassium metabolism modulator</Action><Action id="1834">Ion modulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><LastModificationDate>2017-08-30T03:52:17.000Z</LastModificationDate><ChangeDateLast>2011-12-31T04:24:19.000Z</ChangeDateLast><AddedDate>2010-04-16T10:04:43.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1045924" linkType="Company"&gt;Sorbent Therapeutics&lt;/ulink&gt; was developing CLP-1002, a cross-linked polyelectrolyte polymer with a large saline holding capacity, designed to selectively sequester sodium ions, remove fluid and alter potassium ion levels, for the potential treatment of end-stage renal disease (ESRD) [&lt;ulink linkID="1091025" linkType="Reference"&gt;1091025&lt;/ulink&gt;], [&lt;ulink linkID="1222417" linkType="Reference"&gt;1222417&lt;/ulink&gt;].   In September 2011, the drug was listed as being in phase I development. At that time, the company was seeking to outlicense the drug [&lt;ulink linkID="1222417" linkType="Reference"&gt;1222417&lt;/ulink&gt;]. However, by December 2011, the drug was no longer listed on Sorbent's pipeline [&lt;ulink linkID="1251390" linkType="Reference"&gt;1251390&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Sorbent was previously developing CLP-1002 for the potential treatment of congestive heart failure (CHF). By April 2010, an IND had been filed for CHF  [&lt;ulink linkID="1091025" linkType="Reference"&gt;1091025&lt;/ulink&gt;]. By December 2010, a phase I trial had been ongoing for heart failure [&lt;ulink linkID="1222422" linkType="Reference"&gt;1222422&lt;/ulink&gt;]; however, in September 2011, the indication was no longer listed as being under development [&lt;ulink linkID="1222417" linkType="Reference"&gt;1222417&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Sorbent is also developing &lt;ulink linkID="66147" linkType="Drug"&gt;CLP-1001&lt;/ulink&gt; and investigating &lt;ulink linkID="73467" linkType="Drug"&gt;CLP-1003&lt;/ulink&gt;, for the potential treatment of congestive heart failure.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In April 2008, the company applied for  Fast Track status for CLP-1002; in May 2008, cross-linked polyelectrolyte was given Fast Track designation for  CHF [&lt;ulink linkID="1091025" linkType="Reference"&gt;1091025&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By April 2010, an IND had been filed for ESRD  [&lt;ulink linkID="1091025" linkType="Reference"&gt;1091025&lt;/ulink&gt;]; in September 2011, the drug was listed as being in phase I development [&lt;ulink linkID="1222417" linkType="Reference"&gt;1222417&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1045924">Sorbent Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3251">End stage renal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-29T00:00:00.000Z</StatusDate><Source id="1251390" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1045924">Sorbent Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1045924">Sorbent Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3251">End stage renal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-09-14T00:00:00.000Z</StatusDate><Source id="1222417" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045924">Sorbent Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-04-07T00:00:00.000Z</StatusDate><Source id="1091025" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045924">Sorbent Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="286">Renal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-16T00:00:00.000Z</StatusDate><Source id="1091025" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1045924">Sorbent Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1559">Congestive heart failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1222422" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1045924">Sorbent Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1559">Congestive heart failure</Indication><AwardedIndication>Treatment of congestive heart failure (CHF)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-16T00:00:00.000Z</MileStoneDate><Source id="1091025" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>